Original report
Shanghai, China, June 8, 2026 — Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, announced that the results from the Phase IIb ENLIGHT study of its self-developed next-generation human-derived ultra-long-acting GLP-1 receptor agonist, Efsubaglutide Alfa, for the treatment of overweight and obesity, were presented at the 86th Scientific Sessions of the American Diabetes Association (ADA 2026). The study was presented as a poster, Abstract No. 2636-P.
Image text and data — ENLIGHT phase 2b poster discussion at ADA 2026
Conference participants are pictured discussing a poster in the American Diabetes Association Scientific Sessions poster area. The poster concerns efsubaglutide alfa for overweight or obesity in the ENLIGHT phase 2b study, with study-design information, weight and metabolic-endpoint charts, and safety results. This is a photograph of the poster session; the principal study results are described in the accompanying article.
This randomized, double-blind, placebo-controlled, multicenter study enrolled 200 overweight and obese adults without diabetes to evaluate the efficacy and safety of efsubaglutide alfa at doses ranging from 5 to 20 mg for 18 weeks. Results showed that all dose groups experienced significant weight loss from baseline, superior to the placebo group, and the weight loss was positively correlated with the dose. During treatment, patients in the efsubaglutide alfa group showed a continuous weight loss trend without a plateau.
Doses associated with the ENLIGHT results
The ADA 2026 abstract reports 18-week weight reductions of 10.58% with 20 mg once weekly and 9.70% with 20 mg every two weeks. Other weekly doses were also studied, but these figures apply to those two dose groups. The obesity indication and these dosing regimens remain investigational.
The study employed a simple, rapid dose-titration protocol (incrementing every 2 weeks to reach the target dose of 20 mg within 6 weeks, including once-weekly (QW) and once-every-two-weeks (Q2W) regimens). Results showed that after 18 weeks of treatment including titration and maintenance, efsubaglutide alfa significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively. Meanwhile, the subjects' waist circumference, visceral fat, and liver fat metabolism indicators all showed significant improvement. Notably, the weight loss was primarily due to fat rather than muscle, resulting in a significant increase in the muscle-to-fat ratio of 45.3%; furthermore, liver fat content decreased significantly by 46.9%. Regarding safety, no hypoglycemic events occurred during treatment, and gastrointestinal adverse reactions were mostly mild to moderate, transient, and self-limiting. This study focuses on overweight/obese populations, with the potential to achieve longer dosing intervals, creating a weight loss regimen with high adherence and a superior patient experience, setting a new benchmark for metabolic disease management.
Dr. Qinghua Wang, Founder, Chairman and CEO of Innogen Pharmaceuticals, pointed out that China has a large obese population, which has led to prominent metabolic-related diseases. Moderately to severely obese individuals have become a core focus of clinical intervention and chronic disease prevention. The goal of treatment is not only to achieve weight loss but, more importantly, to improve patients' long-term health outcomes. We are encouraged by the clinical results observed with Efsubaglutide Alfa in this study. In particular, the improvements in body composition and multiple metabolic parameters, alongside substantial weight loss, further strengthen our confidence in the development of next-generation therapies for obesity. Innogen remains committed to advancing innovation in metabolic diseases and expanding the boundaries of treatment through scientific research and development. Our goal is to bring more clinically meaningful therapeutic options to patients worldwide.
Note: Efsubaglutide alfa is approved only for type 2 diabetes; the obesity indication is investigational and not yet approved. This content is for informational purposes only, not an advertisement, advice, or efficacy claim. Use prescription drugs only as directed by a physician.
About Innogen Pharmaceuticals
Founded in 2014, Innogen (HKEX.2591) focuses on innovative metabolic disease drugs, with fully proprietary pipelines covering type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH), and Alzheimer’s disease (AD), supported by global IP and patent portfolios. Its core product, Efsubaglutide Alfa (a next-generation human-derived ultra-long-acting GLP-1 receptor agonist), is approved for type 2 diabetes in Chinese Mainland and Macau SAR, included in China’s National Reimbursement Drug List, and is under global development and registration. Learn more: www.innogenpharm.com.